info@marketresearchfuture.com   📞 +1 (855) 661-4441(US)   📞 +44 1720 412 167(UK)   📞 +91 2269738890(APAC)

QIAGEN & Helix Partners to Develop Companion Diagnostics Products for Hereditary Diseases

By Rahul Gotadki , 17 January, 2023

The demand for companion diagnostics devices and tests that identify clinically relevant genetic abnormalities increases as the development of precision medicines quickens. By identifying patients most likely to benefit from a particular medicinal product or to be at heightened risk, these diagnostics aid clinical decision-making. Companion diagnostics that use whole exome sequencing are mostly used in oncology, but they are widely thought to have significant potential in hereditary disease areas like cardiovascular, metabolic, neuro-degenerative, and auto-immune disorders.

On January 5th, 2023, QIAGEN announced it had entered a strategic partnership with Helix, a US-based population genetics market leader to work together and advance companion diagnostics efforts aimed at hereditary diseases. Through this partnership, QIAGEN will become the exclusive contracting and marketing partner for Helix’s companion diagnostics services. Additionally, QIAGEN will be able to leverage Helix’s laboratory platforms which had received the first-ever US-FDA Class II de novo authorization for whole genome sequencing. Helix will also benefit from getting access to QIAGEN’s diagnostics expertise and its global reach.

QIAGEN has over 30 major collaborations with key pharmaceutical and biotechnology companies globally to develop diagnostic solutions for their drug products. The companion diagnostic products offered by QIAGEN cover a range of technologies, including next-generation sequencing (NGS), polymerase chain reaction (PCR), and digital PCR (dPCR), sample types, including biopsy, and disease areas, including cancer and Parkinson's. There are 11 PCR-based companion diagnostics that have received FDA approval, and a collaboration with Neuron23 to develop an NGS-based companion diagnostic for a novel Parkinson's disease drug was announced in September 2022.

Health systems, life sciences firms, and payers can enhance genomic research and hasten the integration of genomic data into clinical care thanks to end-to-end platform that Helix has created from in order to allow population genomics initiatives with at least 100,000 patients each across the U.S., Helix has teamed with top health systems. These programmes power real-world data (RWD) or real-world evidence (RWE) services and insights and bring deep genetic expertise and methodologies to examine sub-cohorts within both drug discovery and a clinical trial. These programmes also aid in the patient identification and recruitment for clinical trials in hereditary diseases like Parkinson's, cardiovascular or inflammatory diseases like non-alcoholic steatohepatitis (NASH), and power real-world data (RWD) or real-world evidence (RWE) services and insights.

Additionally, according to Thierry Bernard, Chief Executive Officer of QIAGEN, this partnership will also lead to significant developments in the clinical trial space. It will give access to a genomic database that will aid researchers to identify a patient with specific genomic biomarkers in very short intervals, which will shorten trail recruitment steps to a few months from years.

CDx Approved By  FDA, 2022 Data

Data.jpg

Latest News

UK-FUEL-PRICE-2024.jpg
High Cost of Uk Gasoline Prices Fuels Debate

In the past few weeks, the fuel price in the UK has dropped a bit, but it is still expensive for drivers. From 143.15p per liter, unleaded gasoline primarily sells for 136.15p as of last week, while diesel has remained around 141p per Liter. However…

Read More

s-Leadership-in-Global-Oil-Imports.jpg
Asia's Leadership in Global Oil Imports: Consequences for the Automotive Sector in 2025

Asia has retained the position as the top oil importer in 2025, and continues to maintain that critical position in the energy sector that the world relies on. China has retained its top spot as the most prominent crude oil importer since 2013. The…

Read More

Tesla-2025-Crisis.jpg
Tesla’s 2025 Crisis: Why Europe is Turning its Back on Elon Musk’s EV Empire

Once the clear leader in the electric vehicle (EV) sector, Tesla's European market is expected to be drastically declining in 2025. Although CEO Elon Musk is still divisive in the United States, recent registration numbers show a bleak image of…

Read More

-but-Issues-About-Fairness-Loom.jpg
Brits Support Recycling Tax to Address Waste Crisis, but Issues about Fairness Loom

In 2025, the UK government unveiled many essential policies to address the growing trash situation, including a new plastic packaging tax and a landfill fee rise to lessen dependency on landfills. Studies show that over half of Britons support taxes…

Read More

s-Growing-Nuclear-Energy-Development-in-2025.jpg
China’s Growing Nuclear Energy Development in 2025- A Game Changer for Global Energy

Nuclear energy capacity is growing significantly from the beginning of 2025. It is due to increasing concerns over climate change, and energy security amidst fluctuating fuel prices followed by net-zero targets set up by nations globally. Further…

Read More

Author Pic
Rahul Gotadki

Assistant Manager